DCTH (Delcath Systems) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DCTH Delcath Systems Inc DCTH
72 GF Score
Price $13.13
GF Value $37.24
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Delcath Systems 5-Year Yield-on-Cost %?

Delcath Systems DCTH +2.10% 72 5-Year Yield-on-Cost % is 0.00 as of Jul. 14, 2026. GuruFocus rates DCTH with a GF Score™ of 72/100 and a GF Value™ of $37.24 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 327 Medical Devices & Instruments companies, Delcath Systems ranks worse than 305810.09% on this metric.

Delcath Systems's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Delcath Systems's 5-Year Yield-on-Cost % or its related term are showing as below:



DCTH's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.33
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Delcath Systems  (NAS:DCTH) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Delcath Systems 5-Year Yield-on-Cost % Related Terms


DCTH vs VMD, VREX, SI: 5-Year Yield-on-Cost % Comparison

For the Medical Devices subindustry, Delcath Systems's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Delcath Systems 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Delcath Systems's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Delcath Systems's 5-Year Yield-on-Cost % falls into.


DCTH
72GF Score
Delcath Systems Inc DCTH
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Delcath Systems 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Delcath Systems is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Delcath Systems (DCTH) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 14, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Delcath Systems and its competitors. According to the industry distribution chart, Delcath Systems ranks #999999 out of 327 companies in the Medical Devices & Instruments industry.
Is Delcath Systems' 5-Year Yield-on-Cost % too high?
Delcath Systems' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Delcath Systems ranks #999999 out of 327 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Delcath Systems has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Delcath Systems' 5-Year Yield-on-Cost % compare to VMD and VREX?
According to the Medical Devices & Instruments industry distribution chart, Delcath Systems ranks #999999 out of 327 companies for 5-Year Yield-on-Cost %. This places Delcath Systems in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.33, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Delcath Systems and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Delcath Systems's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delcath Systems stock overvalued right now?
Based on GuruFocus' analysis, Delcath Systems (DCTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $37.24, compared to a current price of $13.13 — trading 64.7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Delcath Systems' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Delcath Systems (DCTH), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Delcath Systems (DCTH) Overvalued in 2026?

Based on GuruFocus' analysis, Delcath Systems stock appears to be undervalued. The current stock price of $13.13 is trading 64.7% below its estimated GF Value™ of $37.24. GuruFocus considers Delcath Systems to be Significantly Undervalued.

Key valuation signals for DCTH:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: $37.24 vs. price of $13.13 (64.7% below fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the DCTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Delcath Systems Business Description

Other Exchanges DV3R:Germany
Address 566 Queensbury Avenue, Queensbury, NY, USA, 12804
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
72GF Score

Get the complete analysis for DCTH

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.13
Price
$37.24
GF Value